Position 31 Dec 18 31 Dec 17 Change Cash and cash equivalent 4,023 8,396 - 4,373 Inventories 14,452 9,662 4,790 Current Assets 20,779 19,762 1,017 Net PPE 17,370 3,854 13,516 Intangible Assets-Net 494 482 30

or up by 4.11% and net profit of 1,248.47 million Baht, an increase of 202.25 million Baht or up by 19.33%. This was the result of our ability to control and manage expenses effectively, together with

follows For the three months in Q1/2018 ended March 31, 2018 The company had the operating result for the three months ended March 31, 2018 show a net loss of Baht 6.28 million, compare to the same period

ขายและบริการ – ต้นทุนขายและบริการ (ไม่รวมรายได้อื่น) Q3 2561 Q3 2560 YoY change YoY % change หน่วย: ลา้นบาท รายได้จากการขายและบรกิาร 301.56 201.46 100.10 50% ก าไรจากอัตราแลกเปลีย่น 0.00 0.00 0.00 0

results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech

2016 Pe rfo rm an ce Group Revenues 3,292 2,897 Group Sales Volume (k tons) 182 187 Group EBITDA 213 109 Group Net Profit (Loss) 65 (30) HR C HRC Sales (k tons) 182 187 HRC Production Volume (k tons) 190

rfo rm an ce Revenues 15,178 11,669 Sales Volume (k tons) 812 722 EBITDA 1,062 1,189 Net Profit (Loss) 990 (7) HR C HRC Sales (k tons) 812 722 HRC Production Volume (k tons) 876 733 HRC Average Selling

Year 2017 Year 2016 Pe rfo rm an ce Revenues 15,178 11,669 Sales Volume (k tons) 812 722 EBITDA 1,062 1,189 Net Profit (Loss) 990 (7) HR C HRC Sales (k tons) 812 722 HRC Production Volume (k tons) 876

2017 Pe rfo rm an ce Revenues 7,815 3,276 Sales Volume (k tons) 378 188 EBITDA 118 64 Net Profit (Loss) (451) (233) HR C HRC Sales (k tons) 378 188 HRC Production Volume (k tons) 363 188 HRC Average

Discussion & Analysis Q1/2022 Operating Highlights in Q1/2022 Q1/21 Q1/22 Change +/(-) (THB million) %YoY Operating Revenue 179 198 11% Gross Profit 105 120 14% EBITDA 57 58 2% Net Profit (Loss) for the